<p>根据 Armstrong Advisory Group Inc.在最近向证券交易委员会提交的 13F 表格，该公司在 2023 年第三季度将其在礼来公司（NYSE:LLY - 免费报告）股票中的持仓增加了 53.6%。该机构投资者在此期间购买了 3,062 股后，持有该公司 8,770 股股票。Armstrong Advisory Group Inc.在礼来公司的持股在最近一个季度末价值为 6,691,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也买卖了该公司的股票。Lazard Freres Gestion S.A.S.在第二季度将其在礼来公司的持仓增加了 114.3%。Lazard Freres Gestion S.A.S.现在拥有 77,295 股该公司的股票，价值为 60,253,000 美元，此前在上个季度又购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的持股增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股该公司的股票，价值为 229,000 美元，此前在上个季度又购买了 39 股。Central Pacific Bank Trust Division 在第三季度将其在礼来公司的持股增加了 25.8%。Central Pacific Bank Trust Division 现在拥有 8,990 股该公司的股票，价值为 6,859,000 美元，此前在此期间又购买了 1,843 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的持股增加了 6.8%。Capital Advisors Inc. OK 现在拥有 6,747 股该公司的股票，价值为 5,260,000 美元，此前在上个季度又购买了 429 股。最后，Family CFO Inc 在第二季度购买了礼来公司的新股份，价值约为 54,000 美元。目前 82.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级变动</h2>
<p>一些研究公司最近对 LLY 发布了报告。瑞银集团在周四的研究报告中重申了对礼来公司的 “中性” 评级。汇丰银行在 12 月 10 日的研究报告中重新发布了 “持有” 评级，并对礼来公司的股票设定了 1,070.00 美元的目标价。中金公司研究在 11 月 13 日的研究报告中将礼来公司的目标价从 801.00 美元提高至 1,060.00 美元，并给予该公司 “中性” 评级。加拿大丰业银行在 11 月 13 日的报告中开始覆盖礼来公司。他们对该公司发布了 “行业表现优于大盘” 的评级，并设定了 1,165.00 美元的目标价。最后，古根海姆在 12 月 3 日的研究报告中重申了 “买入” 评级，并设定了 1,163.00 美元的目标价。四位研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 1,141.73 美元。</p>
<ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
<p><strong>阅读我们关于礼来公司的最新研究报告</strong></p>
<h2>礼来公司股票上涨 1.4%</h2>
<p>礼来公司（LLY）周五开盘价为 1,056.57 美元。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该公司的 50 日移动平均线为 956.00 美元，200 日移动平均线为 828.10 美元。该股票的市值为 998.86 亿美元，市盈率为 51.69，市盈增长比率为 1.31，贝塔系数为 0.37。该公司的债务与股本比率为 1.71，流动比率为 1.55，速动比率为 1.24。</p>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）在 10 月 30 日（周四）发布了季度财报。该公司报告季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司在本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。在去年同期，该公司每股收益为 1.18 美元。礼来公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 美元每股收益。研究分析师平均预计礼来公司今年的每股收益为 23.48 美元。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（周二）支付。2 月 13 日（周五）的股东将获得每股 1.73 美元的股息。这相当于年化 6.92 美元的股息，收益率为 0.7%。这比礼来公司之前的季度股息 1.50 美元有所增加。该股息的除息日期为 2 月 13 日（周五）。礼来公司的股息支付比率（DPR）目前为 29.35%。</p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>3 只家居改善股票，可以提升你的投资组合</li>
<li>博通股票暴跌 20%——但华尔街预计其将飙升至 500 美元</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>忘掉芯片：4 个工业领域的投资机会，迎接人工智能反弹</li>
<li>如何选择顶级评级股票</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
<p><strong>想知道其他对 LLY 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在考虑礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Armstrong Advisory Group Inc. 在第三季度将其在礼来的持股增加了 53.6%，目前拥有 8,770 股，价值 6,691,000 美元。其他机构投资者也增加了在礼来的持仓。该股票的平均评级为 “适度买入”，目标价格为 1,141.73 美元。礼来报告了强劲的季度收益，收入同比增长 53.9%</p>

<p>Armstrong Advisory Group Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 53.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,770 shares of the company's stock after purchasing an additional 3,062 shares during the period. Armstrong Advisory Group Inc.'s holdings in Eli Lilly and Company were worth $6,691,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据 Armstrong Advisory Group Inc.在最近向证券交易委员会提交的 13F 表格，该公司在 2023 年第三季度将其在礼来公司（NYSE:LLY - 免费报告）股票中的持仓增加了 53.6%。该机构投资者在此期间购买了 3,062 股后，持有该公司 8,770 股股票。Armstrong Advisory Group Inc.在礼来公司的持股在最近一个季度末价值为 6,691,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Lazard Freres Gestion S.A.S. boosted its position in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company's stock worth $60,253,000 after purchasing an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock valued at $229,000 after purchasing an additional 39 shares in the last quarter. Central Pacific Bank Trust Division lifted its stake in shares of Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock valued at $6,859,000 after purchasing an additional 1,843 shares during the period. Capital Advisors Inc. OK boosted its holdings in Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock worth $5,260,000 after buying an additional 429 shares in the last quarter. Finally, Family CFO Inc purchased a new stake in Eli Lilly and Company during the second quarter worth about $54,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也买卖了该公司的股票。Lazard Freres Gestion S.A.S.在第二季度将其在礼来公司的持仓增加了 114.3%。Lazard Freres Gestion S.A.S.现在拥有 77,295 股该公司的股票，价值为 60,253,000 美元，此前在上个季度又购买了 41,222 股。Precedent Wealth Partners LLC 在第二季度将其在礼来公司的持股增加了 15.3%。Precedent Wealth Partners LLC 现在拥有 294 股该公司的股票，价值为 229,000 美元，此前在上个季度又购买了 39 股。Central Pacific Bank Trust Division 在第三季度将其在礼来公司的持股增加了 25.8%。Central Pacific Bank Trust Division 现在拥有 8,990 股该公司的股票，价值为 6,859,000 美元，此前在此期间又购买了 1,843 股。Capital Advisors Inc. OK 在第二季度将其在礼来公司的持股增加了 6.8%。Capital Advisors Inc. OK 现在拥有 6,747 股该公司的股票，价值为 5,260,000 美元，此前在上个季度又购买了 429 股。最后，Family CFO Inc 在第二季度购买了礼来公司的新股份，价值约为 54,000 美元。目前 82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research firms have recently issued reports on LLY. UBS Group reiterated a &#34;neutral&#34; rating on shares of Eli Lilly and Company in a research report on Thursday. HSBC reissued a &#34;hold&#34; rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. CICC Research increased their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, November 13th. Scotiabank assumed coverage on Eli Lilly and Company in a report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $1,165.00 price target for the company. Finally, Guggenheim reaffirmed a &#34;buy&#34; rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $1,141.73.</p>
<div class="lb-trans"><p>一些研究公司最近对 LLY 发布了报告。瑞银集团在周四的研究报告中重申了对礼来公司的 “中性” 评级。汇丰银行在 12 月 10 日的研究报告中重新发布了 “持有” 评级，并对礼来公司的股票设定了 1,070.00 美元的目标价。中金公司研究在 11 月 13 日的研究报告中将礼来公司的目标价从 801.00 美元提高至 1,060.00 美元，并给予该公司 “中性” 评级。加拿大丰业银行在 11 月 13 日的报告中开始覆盖礼来公司。他们对该公司发布了 “行业表现优于大盘” 的评级，并设定了 1,165.00 美元的目标价。最后，古根海姆在 12 月 3 日的研究报告中重申了 “买入” 评级，并设定了 1,163.00 美元的目标价。四位研究分析师对该股票给予了强烈买入评级，十七位给予了买入评级，五位给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 1,141.73 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
</div><p><strong>Read Our Latest Research Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于礼来公司的最新研究报告</strong></p>
</div><h2>Eli Lilly and Company Stock Up 1.4%</h2>
<div class="lb-trans"><h2>礼来公司股票上涨 1.4%</h2>
</div><p>LLY opened at $1,056.57 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The business has a 50-day moving average of $956.00 and a two-hundred day moving average of $828.10. The stock has a market capitalization of $998.86 billion, a price-to-earnings ratio of 51.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.</p>
<div class="lb-trans"><p>礼来公司（LLY）周五开盘价为 1,056.57 美元。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。该公司的 50 日移动平均线为 956.00 美元，200 日移动平均线为 828.10 美元。该股票的市值为 998.86 亿美元，市盈率为 51.69，市盈增长比率为 1.31，贝塔系数为 0.37。该公司的债务与股本比率为 1.71，流动比率为 1.55，速动比率为 1.24。</p>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company's revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）在 10 月 30 日（周四）发布了季度财报。该公司报告季度每股收益为 7.02 美元，超出市场共识预期的 6.42 美元，超出幅度为 0.60 美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。该公司在本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。在去年同期，该公司每股收益为 1.18 美元。礼来公司的季度收入同比增长 53.9%。礼来公司已将其 2025 财年的指导目标设定为 23.000-23.700 美元每股收益。研究分析师平均预计礼来公司今年的每股收益为 23.48 美元。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（周二）支付。2 月 13 日（周五）的股东将获得每股 1.73 美元的股息。这相当于年化 6.92 美元的股息，收益率为 0.7%。这比礼来公司之前的季度股息 1.50 美元有所增加。该股息的除息日期为 2 月 13 日（周五）。礼来公司的股息支付比率（DPR）目前为 29.35%。</p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>How to Choose Top Rated Stocks</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过礼来公司</li>
<li>3 只家居改善股票，可以提升你的投资组合</li>
<li>博通股票暴跌 20%——但华尔街预计其将飙升至 500 美元</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>忘掉芯片：4 个工业领域的投资机会，迎接人工智能反弹</li>
<li>如何选择顶级评级股票</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 LLY 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取礼来公司（NYSE:LLY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

阿姆斯特朗咨询集团公司增加了对礼来公司（Eli Lilly）的股票持有量 $LLY